SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.
Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical Trials
Central monitoring aims at improving the quality of clinical research by pro-actively identifying risks and remediating emerging issues in the conduct of a clinical trial that may have an adverse impact on patient safety and/or the reliability of trial results.
Trendspotting: What’s Coming for Clinical Trials and Research in 2024
We spoke with leaders and experts in the Clinical Research community about their predictions for 2024.
Ukraine War’s Impact on Clinical Research: Evidence from Key Risk Indicators
Key risk indicators (KRIs) are commonly used as an important component of central monitoring to enable study teams to detect emerging quality issues of interest during a clinical trial. Given the large volume of KRI-related information now available for global clinical trials on the CluePoints risk-based quality management (RBQM) platform, we decided to take the […]
Using Machine Learning and NLP to Improve Central Monitoring Documentation
Central monitoring helps sponsors to proactively identify and remediate data quality issues during the conduct of clinical trials.
DIA Global Forum: Statistics Powering Risk-Based Quality Management
CluePoints Co-Founder and Chief Product & Technology Officer François Torche discusses the challenges of collecting clinical trial data with digital or remote tools (eCOA, ePRO, etc.) without putting the quality of that collected data at risk in the below interview.
Solving the Rubik’s Cube of Competing Forces to Realize the Future of Clinical Research
Artificial intelligence (AI) has massive potential to advance clinical research.
DIA 2023 Topic: The Industry-Wide Definition for RBQM
At the recent DIA 2023 Global Annual Conference, I focused my attention on discussions about the need for clear processes for reviewing audit trails, overseeing decentralized clinical trial (DCT) data, the impact of ICH E6(R3) on these areas, and the need for an industry-wide definition of Risk-Based Quality Management (RBQM).
Statistics Powering Risk-Based Quality Management
CluePoints Co-Founder and Chief Product & Technology Officer François Torche discusses the challenges of collecting clinical trial data with digital or remote tools (eCOA, ePRO, etc.) without placing the quality of that collected data at risk, in this DIA Global Annual Meeting 2023 interview.
RBQM Adoption: Current Use, Overcoming Barriers, And Anticipating ICH E6 (R3)
A conversation with Steve Young, member of Avoca Quality Consortium, PHUSE Working Group participant, and Tufts survey contributor
